October 9, 2026 · Patent expires April 11, 2031

Ingrezza (valbenazine): The 2031-2038 Generic Opportunity Window

Neurocrine Biosciences' blockbuster Ingrezza (valbenazine) generated over $2.51 billion in revenue in 2025 as a critical therapy for tardive dyskinesia, but its core composition patent (US 8,039,627) is approaching expiry on April 11, 2031. Following Hatch-Waxman Paragraph IV litigation, Neurocrine reached settlement agreements with generic challengers including Lupin Limited. These agreements authorize generic market entry beginning March 1, 2038, establishing a definitive 2031-2038 opportunity window.

What we do

We track expirations like this continuously

This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.